Nifurtimox
Nifurtimox structure
|
Common Name | Nifurtimox | ||
|---|---|---|---|---|
| CAS Number | 23256-30-6 | Molecular Weight | 287.29200 | |
| Density | 1.56g/cm3 | Boiling Point | 550.3ºC at 760mmHg | |
| Molecular Formula | C10H13N3O5S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 286.6ºC | |
|
Trypanocidal Activity of Long Chain Diamines and Aminoalcohols.
Molecules 20 , 11554-68, (2015) Thirteen aminoalcohols and eight diamines were obtained and tested against Trypanosoma cruzi epimastigotes strains MG, JEM and CL-B5 clone. Some of them were equal or more potent (1.0-6.6 times) than the reference compound nifurtimox. From them, three aminoal... |
|
|
American Trypanosomiasis (Chagas Disease)
Infect. Dis. Clin. North Am. 26(2) , 275-91, (2012) Chagas disease, also known as American trypanosomiasis, is a chronic infection caused by Trypanosoma cruzi, a protozoan parasite. It is transmitted to human beings mainly through the feces of infected triatomine bugs. The disease affects an estimated 8 to 10 ... |
|
|
Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs.
Antimicrob. Agents Chemother. 56(11) , 5821-30, (2012) Nitroheterocyclic prodrugs are used to treat infections caused by Trypanosoma cruzi and Trypanosoma brucei. A key component in selectivity involves a specific activation step mediated by a protein homologous with type I nitroreductases, enzymes found predomin... |
|
|
Antiparasitic prodrug nifurtimox: revisiting its activation mechanism.
Future Microbiol. 6(8) , 847-50, (2011) EVALUATION OF: Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J. Biol. Chem. 286, 13088-13095 (2011). The prodrug nifurtimox has been one of the pharmacologic alternatives to... |
|
|
Study of Trypanosoma cruzi epimastigote cell death by NMR-visible mobile lipid analysis.
Parasitology 139(4) , 506-15, (2012) Cell death mechanisms in Trypanosoma cruzi have not been disclosed in detail though different conventional techniques have been used in the classification of parasite-cell death type. Nuclear magnetic resonance (NMR) has successfully been used as a tool to ev... |
|
|
Follicular atresia in the prepubertal spiny mouse (Acomys cahirinus) ovary.
Apoptosis 16(10) , 967-75, (2011) This study was designed to determine follicular atresia in the newborn and the prepubertal spiny mouse. We analyzed the processes of follicle loss using classical markers of apoptosis (TUNEL reaction, active caspase-3) and autophagy (Lamp1). Numerous small cl... |
|
|
Microsatellite and mini-exon analysis of Mexican human DTU I Trypanosoma cruzi strains and their susceptibility to nifurtimox and benznidazole.
Vector Borne Zoonotic Dis. 13(3) , 181-7, (2013) Chagas disease is caused by the protozoan parasite Trypanosoma cruzi, and it affects as many as 10 million people in North and South America, where it represents a major public health problem. T. cruzi is a parasite with high genetic diversity, and it has bee... |
|
|
Reactivation of Chagas' disease: cutaneous manifestations in two immunosuppressed patients.
Int. J. Dermatol. 51(7) , 829-34, (2012) Chagas' disease is a zoonosis caused by a protozoan agent, Trypanosoma cruzi. Patients undergoing immunosuppressive treatment due to organ transplant, malignancies, infections, or chemotherapy may reactivate a preexisting chronic or indeterminate Trypanosoma ... |
|
|
The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein.
Brain Res. 1436 , 111-21, (2012) Human African trypanosomiasis (HAT) is a parasitic disease affecting sub-Saharan Africa. The parasites are able to traverse the blood-brain barrier (BBB), which marks stage 2 (S2) of the disease. Delivery of anti-parasitic drugs across the BBB is key to treat... |
|
|
[Using S35-S36 and TcH2AF-R primer-based PCR tests to follow-up a Chagas´ disease patient who had undergone a heart transplant].
Biomedica. 31(2) , 178-84, (2011) Cardiomyopathy is the most common clinical form of Chagas' disease in Colombia, and one treatment option is a heart transplant. Tracking the behavior of the Chagas' parasite, Trypanosoma cruzi, is a priority due to the risk of post-transplant reactivation of ... |